Expert Interview
A look at the use of Treprostinil in PAH and the potential of Liquidia's Yutrepia DPI in the market
Ticker(s): LQDA, UTHRInstitution: UPENN
- Chief, Pulmonary, Allergy and Critical Care, Penn Presbyterian Medical Center, Director, Pulmonary Vascular Disease Program and Professor of Medicine at the Hospital of the University of Pennsylvania.
- Treats ~200 patients with PAH.
- Research focuses on the diagnosis and treatment of pulmonary vascular disease and pulmonary thromboembolic disease.
How many patients do you see with Pulmonary arterial hypertension and specifically with pulmonary hypertension with Interstitial Lung Disease (PH-ILD)?
Please comment on the findings of the Yutrepia INSPIRE study: -YUTREPIA can be safely titrated using a dry powder inhaler to doses comparable to 24 breaths of Tyvaso, indicating that a wide range of therapeutic doses can be more easily administered in just a few breaths compared to nebulizers-At Month 12, 79% of Transition patients and 91% of Naïve patients achieved a dose greater than or equal to 79.5 mcg YUTREPIA, the comparable dose to 9 breaths of Tyvaso, four times a day-6MWD. A slight increase in the 6MWD in Naïve and Transition patients, with larger increases evident in the Transition group which remained stable at Month 12.
-NYHA Functional Class. An increase in the percentage of patients in New York heart Association (NYHA) Functional Class I and II for both Naïve and Transition groups, compared with baseline, was observed at Month 2 and maintained at Month 12. -PAH Risk Score. A higher percentage of patients had two or more low risk criteria at Months 2, 4, 8, and 12. At Month 12, the percentage of patients meeting 2 or 3 low-risk criteria was 59.0% for Naïve patients and 67.8% for Transition patients.-NT-proBNP levels. Variable changes in the levels of N-terminal-pro hormone BNP (NT-proBNP) with no clear trends in Transition patients, though Naïve patients saw a progressive decline from Month 4 to Month 12.-Quality of Life. Overall, there was a clinically meaningful improvement from baseline to Month 2 and Month 4 in Minnesota Living with Heart Failure questionnaire (MLHFQ) total score, with significant decreases in both emotional and physical dimension scores in both patient groups. The MLHFQ was not administered after Month 4.-Device preference. All the Transition patients preferred or strongly preferred the YUTREPIA device when surveyed about their preferences compared to nebulized Tyvaso at Month 4.-Both Naïve and Transition patients maintained or improved in exploratory measures of clinical efficacy; however, the study was not designed or controlled to make definitive statements
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
